"Pyridazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
| Descriptor ID |
D011724
|
| MeSH Number(s) |
D03.383.710
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridazines".
Below are MeSH descriptors whose meaning is more specific than "Pyridazines".
This graph shows the total number of publications written about "Pyridazines" by people in this website by year, and whether "Pyridazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 2 | 5 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 4 | 1 | 5 |
| 2015 | 4 | 1 | 5 |
| 2016 | 3 | 1 | 4 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 3 | 0 | 3 |
| 2022 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridazines" by people in Profiles.
-
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol. 2024 Nov; 11(11):e839-e849.
-
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. Am J Hematol. 2024 Nov; 99(11):2229-2232.
-
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol. 2024 Dec 20; 42(36):4246-4251.
-
Levosimendan for Diastolic Dysfunction? Cardiovasc Drugs Ther. 2024 Oct; 38(5):1053-1054.
-
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2024 06 04; 331(21):1814-1823.
-
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer. 2024 Oct 01; 130(19):3344-3352.
-
Effects of focal cortical cooling on somatosensory evoked potentials in rats. Brain Res. 2024 Oct 01; 1840:148995.
-
Ponatinib-review of historical development, current status, and future research. Am J Hematol. 2024 08; 99(8):1576-1585.
-
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol. 2024 07; 99(7):1423-1426.
-
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 03; 38(3):475-481.